Company intelligence / Profile preview
IgGenix
South San Francisco, California, United Statesiggenix.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
IgGenix has advanced its lead candidate IGNX001, a first-in-class monoclonal antibody for peanut allergy, into a Phase 1 clinical trial ("ACCELERATE Peanut Study") to evaluate safety and tolerability. The company has presented supporting data at major conferences and continues to expand its pipeline targeting food and environmental allergies using its proprietary SEQ SIFTER™ platform. No efficacy results have been published yet as the program remains early-stage.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Engineered human IgG antibodies derived from allergen-specific IgE B cells
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on IgGenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IgGenix.